As of 10:10 AM EST. Market Open. NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other best small-cap stocks to buy according to analysts. During the third quarter of 2024 ...

Despite past poor performance, recent positive data and a strong cash balance make ARVN a cautiously optimistic investment ahead of upcoming phase 3 data. Financially, Arvinas has a market cap of ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $48.00. The company’s shares closed last ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), 2seventy bio (TSVT – Research Report ...

Margaret Atwood's 1985 dystopian classic saw a 1,826 percent increase on the retailer's Movers & Shakers list the day after ...

Arvinas Holding Company ( (ARVN)) has realeased its Q3 earnings. Here is a breakdown of the information Arvinas Holding Company presented to its investors. Arvinas, Inc. (Nasdaq: ARVN ...

Swiss pharma giant Novartis AG (NYSE: NVS) reported better-than-expected results for the second quarter of 2024. Core earnings (excluding one-time charges) of $1.97 per share beat the Zacks ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...